Clinical Trials Sponsored by Dainippon Sumitomo Pharma

Total 116 results

Sumitomo Pharma Co., Ltd.

Completed

Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Japan
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Schizophrenia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Japan
Sumitomo Pharma Co., Ltd.

Completed

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Solid Tumors

Japan
Sumitomo Pharma Co., Ltd.

Completed

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Malaysia, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Lung Cancer

Japan
Sumitomo Pharma Switzerland GmbH

Not yet recruiting

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk
Sumitomo Pharma America, Inc.

Recruiting

A Study of Oral TP-3654 in Patients With Myelofibrosis

Myelofibrosis

United States, Belgium, France, Japan, Australia, Italy, United Kingdom
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (REPLACE-CV)

Prostate Cancer

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
Sumitomo Pharma America, Inc.

Completed

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (SERENE)

Contraception

United States, Puerto Rico
Sumitomo Pharma America, Inc.

Enrolling by invitation

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Terminated

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Depressive Episodes, Bipolar I Depression

United States, Bulgaria, Japan
Sumitomo Pharma America, Inc.

Completed

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Parkinson Disease

United States, Spain, United Kingdom, Italy, Canada, Austria, France, Germany
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Depressive Episodes, Bipolar I Depression

United States, Bulgaria, Japan, Romania, Canada, Slovakia
Sumitomo Pharma America, Inc.

Terminated

Alvocidib Biomarker-driven Phase 2 AML Study

Acute Myeloid Leukemia

United States, Spain, Canada, United Kingdom
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Canada
Sumitomo Pharma America, Inc.

Completed

Study of TP-3654 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Sumitomo Pharma America, Inc.

Withdrawn

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Renal Cell Carcinoma | Urothelial Carcinoma | Urologic Malignancies
Sumitomo Pharma America, Inc.

Completed

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

Cancer, Advanced Solid Tumors

United States, Canada
Sumitomo Pharma America, Inc.

Completed

First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Malignancies

Cancer, Advanced Malignancies

Canada, United States
Sumitomo Pharma America, Inc.

Completed

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Melanoma | Sarcoma | Renal Cell Carcinoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Glioblastoma Multiforme

United States
Sumitomo Pharma America, Inc.

Completed

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Recurrent Ovarian Carcinoma | Colorectal Carcinoma | EGFR Positive Non-small Cell Lung Cancer | BRAF-Mutated Melanoma

United States
Sumitomo Pharma America, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

Drug-drug Interactions

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Cancer | Advanced Solid Tumors

United States
Sumitomo Pharma America, Inc.

Completed

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Healthy | ADME

United States
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Glioblastoma | Diffuse Intrinsic Pontine Glioma

Japan
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Schizophrenia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Bipolar Depression

Lithuania, Malaysia, Russian Federation, Slovakia, Ukraine, Japan, Philippines, Taiwan
Sumitomo Pharma Co., Ltd.

Terminated

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Small-cell Lung Cancer

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Bipolar I Disorder

Japan, Lithuania, Malaysia, Philippines, Russian Federation, Slovakia, Taiwan, Ukraine
Sumitomo Pharma Co., Ltd.

Completed

Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy

Diabetic Neuropathy

Canada
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Lung Cancer

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

A Clinical Trial of Lurasidone in Treatment of Schizophrenia

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients (AHOCEP)

Chronic Kidney Disease

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

First Episode Schizophrenia | Social Function | Cognition Function | Blonanserin

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

Schizophrenia

China
AbbVie
Sumitomo Pharma Oncology, Inc.

Completed

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States, Germany, United Kingdom
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder (TACGAD)

Generalized Anxiety Disorder

China

3

Subscribe